03Aug 2024
Abemaciclib Enhances OS in HR+/HER2- Advanced Breast Cancer

Abemaciclib Enhances OS in HR+/HER2- Advanced Breast Cancer

The MONARCH-3 trial final analysis shows that abemaciclib plus an aromatase inhibitor improves median overall survival in HR+/HER2- advanced breast cancer compared to placebo, though the result is not statistically significant (p=0.0664).

  • #oncology

Like

Save

Share